Grapevine, United States
Versant Diagnostics, with the slogan "The future of pathology starts here," is an independent physician services company driving the digital revolution in the healthcare industry. Founded in 2019 by leading physician and operating executives Ven Aduana, M.D., Jim Billington, and Brian Carr, the company is actively seeking to acquire the best pathology groups in the nation. Their goal is to provide these groups with the necessary resources to transition to digital pathology, all while preserving the expert leadership of their physicians.
Combining technological advancements in healthcare with a skilled and diverse set of subspecialty pathologists, Versant Diagnostics is positioned to deliver unprecedented service and become the trusted go-to pathology network for hospitals and physician practices across the country. The company operates in the Health Care industry and is headquartered in the United States.
The most recent investment in Versant Diagnostics was a Private Equity Round investment on 27 October 2021, with key investors including Sweetwater Capital Partners, BPEA, and Iron Path Capital. With its innovative approach to pathology and strong investor support, Versant Diagnostics is poised for significant growth and impact in the healthcare sector.
